Direkt zum Inhalt
Merck
Alle Fotos(1)

Wichtige Dokumente

Gesamtdokumentation anzeigen

1448901

USP

Mupirocin

United States Pharmacopeia (USP) Reference Standard

Synonym(e):

5,9-Anhydro-2,3,4,8-tetradeoxy-8-[[3-(2-hydroxy-1-methylpropyl)oxiranyl]methyl]-3-methyl-[2E,8[2S,3S(1S,2S)]]-L-talonon-2-enonic acid 8-carboxyoctyl ester, BRL 4910A, Pseudomonic acid

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise

Größe auswählen

50 MG
CHF 391.00

CHF 391.00

Check Cart for Availability
Bulk-Bestellung anfordern
Alle Fotos(1)

Größe auswählen

Ansicht ändern
50 MG
CHF 391.00

About This Item

Empirische Formel (Hill-System):
C26H44O9
CAS-Nummer:
12650-69-0
Molekulargewicht:
500.62
MDL-Nummer:
MFCD01711620
UNSPSC-Code:
41116107
PubChem Substanz-ID:
329750503
NACRES:
NA.24

CHF 391.00

Check Cart for Availability
Bulk-Bestellung anfordern

Qualität

pharmaceutical primary standard

API-Familie

mupirocin

Hersteller/Markenname

USP

Anwendung(en)

pharmaceutical (small molecule)

Format

neat

SMILES String

[H][C@@]1(CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)[C@H](O)[C@@H]1O)C[C@@H]2O[C@@]2([H])[C@@H](C)[C@H](C)O

InChI

1S/C26H44O9/c1-16(13-23(30)33-11-9-7-5-4-6-8-10-22(28)29)12-20-25(32)24(31)19(15-34-20)14-21-26(35-21)17(2)18(3)27/h13,17-21,24-27,31-32H,4-12,14-15H2,1-3H3,(H,28,29)/b16-13+/t17-,18-,19-,20-,21-,24+,25-,26-/m0/s1

InChIKey

MINDHVHHQZYEEK-HBBNESRFSA-N

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Verwandte Kategorien

Allgemeine Beschreibung

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Anwendung

Mupirocin USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Biochem./physiol. Wirkung

Antibiotic; inhibits isoleucyl-tRNA synthetase (IRS).

Hinweis zur Analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Sonstige Hinweise

Sales restrictions may apply.

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 2

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Dokumente section.

Wenn Sie Hilfe benötigen, wenden Sie sich bitte an Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Slide 1 of 6

1 of 6

Fusidinsäure European Pharmacopoeia (EP) Reference Standard

Y0001411

Fusidinsäure

Fluticasonpropionat Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1702

Fluticasonpropionat

Tobramycin Aminoglycoside antibiotic

Sigma-Aldrich

T4014

Tobramycin

Mucin aus Rinderunterkieferdrüse Type I-S

Sigma-Aldrich

M3895

Mucin aus Rinderunterkieferdrüse

BSM-Aagar suitable for microbiology, NutriSelect® Basic

Millipore

88517

BSM-Aagar

Nystatin powder, BioReagent, suitable for cell culture

Sigma-Aldrich

N6261

Nystatin

J S Bertino
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 54(19), 2185-2191 (1997-10-23)
The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosage and administration of mupirocin are reviewed. Mupirocin is a naturally occurring antibiotic produced by submerged fermentation of Pseudomonas fluorescens. It inhibits bacterial protein synthesis by binding reversibly and specifically to isoleucyl-tRNA
Gaosi Xu et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 25(2), 587-592 (2009-08-15)
Recently, there have been increasing concerns about the emergence of mupirocin resistance and increased infections due to lowered inhibition of Staphylococcus aureus. We conducted this systemic analysis to find out whether the application of mupirocin was effective for the prevention
T Coates et al.
The Journal of antimicrobial chemotherapy, 64(1), 9-15 (2009-05-20)
Staphylococcus aureus in the nose is a risk factor for endogenous staphylococcal infection. UK guidelines recommend the use of mupirocin for nasal decolonization in certain groups of patients colonized with methicillin-resistant S. aureus (MRSA). Mupirocin is effective at removing S.
B D Cookson
The Journal of antimicrobial chemotherapy, 41(1), 11-18 (1998-03-25)
Mupirocin was introduced into clinical practice in the UK in 1985, and has proved to be an extremely effective treatment of skin infections and one of the most successful topical antibiotics for the clearance of nasal Staphylococcus aureus isolates including
Kevin B Laupland et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 37(7), 933-938 (2003-09-18)
Most Staphylococcus aureus infections are endogenously acquired, and treatment of nasal carriage is one potential strategy for prevention. We critically appraised the published evidence regarding the efficacy of intranasal mupirocin for eradication of S. aureus nasal carriage and for prophylaxis
Alle zugehörigen Dokumente anzeigen

Questions

Reviews

No rating value

Active Filters

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.